Welcome to our dedicated page for Replimune Group news (Ticker: REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group stock.
Replimune Group, Inc. reports clinical, regulatory and financial developments for a clinical-stage biotechnology business developing oncolytic immunotherapies for cancer. The company’s proprietary RPx platform uses an engineered HSV-1 backbone intended to promote tumor cell killing, immunogenic cell death and systemic anti-tumor immune responses.
Recurring Replimune news centers on RP1, or vusolimogene oderparepvec, including data from the IGNYTE clinical trial, combination use with nivolumab in advanced melanoma, Biologics License Application activity and FDA complete response letters. Updates also cover RP2 clinical data in advanced solid tumors, scientific presentations at oncology meetings, quarterly financial results, research and development spending, cash runway commentary and management presentations at healthcare conferences.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.